

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595


**Amendment to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1 -46. (Cancelled)

47. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form  $-C(R_5)=N-$ ;

Y is  $-C(R_5)-$  and taken together with the carbon atom bearing the phenyl group forms a double bond and R<sub>1</sub> is absent;

Y' is  $-N(R_5)-$ ;

Z forms a covalent single bond between X' and Y';

R<sub>2</sub> and R<sub>4</sub> are independently selected from hydrogen and C<sub>1-3</sub>alkyl;

R<sub>3</sub> is selected from C<sub>1-3</sub>alkyl and (A)<sub>m</sub>R<sub>12</sub>;

$-C(R_5)-$  is selected from  $-C(H)-$  and  $-C(C_{1-20}alkyl)-$ ;

$-N(R_5)-$  is selected from  $-N(H)-$  and  $-N(C_{2-20}alkyl)-$ ;

m is 0;


AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595

$R_{12}$  is selected from the group consisting of OH, SH,  $\text{NH}_2$ , halo,  $\text{NO}_2$ ,  $\text{C}(\text{R}_{17})_3$ ,  $\text{OC}(\text{R}_{17})_3$  and CN; and

$R_{17}$  is independently selected from hydrogen and halogen; ~~and~~

~~wherein each alkyl may be optionally substituted.~~

48. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt or ~~prodrug~~ thereof



wherein

X and X' taken together form  $-\text{C}(\text{R}_5)=\text{N}-$ ;

Y is  $-\text{C}(\text{R}_5)-$  and taken together with the carbon atom bearing the phenyl group forms a double bond and  $\text{R}_1$  is absent;

Y' is  $-\text{N}(\text{R}_5)-$ ;

Z forms a covalent single bond between X' and Y';

$\text{R}_2$  and  $\text{R}_4$  are independently selected from hydrogen and  $\text{C}_{1-3}$ alkyl;

$\text{R}_3$  is selected from  $\text{C}_{1-3}$ alkyl and  $(\text{A})_m\text{R}_{12}$ ;

$-\text{C}(\text{R}_5)-$  is selected from  $-\text{C}(\text{H})-$  and  $-\text{C}(\text{C}_{1-20}\text{alkyl})-$ ;

$-\text{N}(\text{R}_5)-$  is selected from  $-\text{N}(\text{alkyl})-$  wherein alkyl is selected from the group consisting of ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *t*-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595

m is 0;

R<sub>12</sub> is selected from the group consisting of OH, SH, NH<sub>2</sub>, halo, NO<sub>2</sub>, C(R<sub>17</sub>)<sub>3</sub>, OC(R<sub>17</sub>)<sub>3</sub> and CN;

R<sub>17</sub> is independently selected from hydrogen and halogen; and  
wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is -CH-; and

X is -CH-.

50. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is OC(R<sub>17</sub>)<sub>3</sub>.

51. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is C<sub>1-3</sub>alkyl.

52. (Previously presented) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is -CH<sub>3</sub> or -OCH<sub>3</sub>.

53. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R<sub>5</sub>)- is -N(3-methylbutyl).

54. (Previously presented) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (Previously presented) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (Previously presented) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (Previously presented) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.